Chih-Jian Lih Selected Research

Sudden Death

1/2019

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chih-Jian Lih Research Topics

Disease

11	Neoplasms (Cancer) 01/2021 - 08/2006
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 08/2017 - 02/2014
2	Breast Neoplasms (Breast Cancer) 01/2018 - 01/2016
1	Sudden Death 01/2019
1	Neuroendocrine Carcinoma 01/2019
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2019
1	Colonic Neoplasms (Colon Cancer) 01/2018
1	Anemia 08/2017
1	Leukopenia 08/2017
1	Neutropenia 08/2017
1	Thrombocytopenia (Thrombopenia) 08/2017
1	Ovarian Neoplasms (Ovarian Cancer) 04/2015
1	Fallopian Tube Neoplasms 04/2015
1	Adenocarcinoma 01/2015
1	Leukemia 02/2014
1	Lymphoma (Lymphomas) 02/2014
1	Arthritis (Polyarthritis) 10/2012
1	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 10/2012
1	Macrophage Activation Syndrome 03/2012
1	Inflammation (Inflammations) 07/2008
1	Prostatic Neoplasms (Prostate Cancer) 08/2006

Drug/Important Bio-Agent (IBA)

6	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2015
3	Biological ProductsIBA 01/2018 - 10/2012
2	veliparibIBA 01/2021 - 04/2015
2	Proteins (Proteins, Gene)FDA Link 10/2020 - 08/2006
2	ibrutinibIBA 01/2019 - 08/2015
1	trametinibIBA 01/2021
1	Everolimus FDA Link 01/2021
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021
1	Temozolomide (Temodar)FDA LinkGeneric 01/2021
1	Carboplatin (JM8)FDA LinkGeneric 01/2021
1	adavosertibIBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 10/2020
1	Co-Repressor ProteinsIBA 10/2020
1	TensinsIBA 10/2020
1	MutL Protein Homolog 1IBA 10/2020
1	MutS ProteinsIBA 10/2020
1	obinutuzumabIBA 01/2019
1	Chlorambucil (Leukeran)FDA Link 01/2019
1	Carrier Proteins (Binding Protein)IBA 01/2018
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 08/2017
1	Rituximab (Mabthera)FDA Link 08/2017
1	Lenalidomide (CC 5013)FDA Link 08/2017
1	Gemcitabine FDA Link 08/2017
1	Etoposide (VP 16)FDA LinkGeneric 08/2017
1	Messenger RNA (mRNA)IBA 04/2015
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2015
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 04/2015
1	ParaffinIBA 02/2014
1	carboxyl radical (COO-)IBA 02/2014
1	Formaldehyde (Formol)FDA Link 02/2014
1	Syntex adjuvant formulationIBA 10/2012
1	Interleukin-4 (Interleukin 4)IBA 10/2012
1	Interleukin-10 (Interleukin 10)IBA 10/2012
1	CytokinesIBA 03/2012
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2008
1	taxaneIBA 08/2006
1	Paclitaxel (Taxol)FDA LinkGeneric 08/2006
1	Thrombospondin 1IBA 08/2006

Therapy/Procedure

6	Therapeutics 01/2021 - 02/2014
1	Drug Therapy (Chemotherapy) 01/2019
1	Precision Medicine 01/2017